Mydecine Innovations Group Inc. announced that it has share promising pharmacokinetics and pharmacodynamics results from the MYCO-006 family in mouse models. The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration.

The Company believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized "psychedelic clinic" where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. As compared to Gen-1 MDMA, this provides a huge cost savings in physician hours and allows more patients to be treated in the same amount of time. Mydecine's latest studies show that the cell receptor level activity and time course of the MYCO-006 family are consistent with the program's goals.

MYCO-006 compounds are projected to last one-third as long as MDMA, lasting around one to two hours vs the conventional six to eight hours duration of Gen-1 MDMA, with a four-fold onset increase. The MYCO-006 family of medication candidates is protected by numerous layers of pending patent claims, which have been fully disclosed and include, among other things, composition of matter, granting Mydecine exclusive use of these prospective pharmaceuticals for the next two decades. PTSD, anxiety, depression, addiction and chronic pain are among the potential indications being considered for MYCO-006 use.